We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Adma Biologics (ADMA) Registers a Bigger Fall Than the Market: Important Facts to Note
Read MoreHide Full Article
Adma Biologics (ADMA - Free Report) ended the recent trading session at $14.99, demonstrating a -4.34% change from the preceding day's closing price. The stock's change was less than the S&P 500's daily loss of 1.52%. Elsewhere, the Dow lost 1.56%, while the tech-heavy Nasdaq lost 1.78%.
Shares of the infectious disease drug developer have depreciated by 3.75% over the course of the past month, underperforming the Medical sector's loss of 3.1%, and the S&P 500's loss of 2.25%.
Market participants will be closely following the financial results of Adma Biologics in its upcoming release.
For the full year, the Zacks Consensus Estimates are projecting earnings of $0.96 per share and revenue of $639.74 million, which would represent changes of +60% and +25.4%, respectively, from the prior year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Adma Biologics. These revisions help to show the ever-changing nature of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 12.35% higher. Adma Biologics is currently a Zacks Rank #1 (Strong Buy).
Investors should also note Adma Biologics's current valuation metrics, including its Forward P/E ratio of 16.41. For comparison, its industry has an average Forward P/E of 18.67, which means Adma Biologics is trading at a discount to the group.
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 86, positioning it in the top 36% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
View the Zacks #1 Rank List
Image: Bigstock
Adma Biologics (ADMA) Registers a Bigger Fall Than the Market: Important Facts to Note
Adma Biologics (ADMA - Free Report) ended the recent trading session at $14.99, demonstrating a -4.34% change from the preceding day's closing price. The stock's change was less than the S&P 500's daily loss of 1.52%. Elsewhere, the Dow lost 1.56%, while the tech-heavy Nasdaq lost 1.78%.
Shares of the infectious disease drug developer have depreciated by 3.75% over the course of the past month, underperforming the Medical sector's loss of 3.1%, and the S&P 500's loss of 2.25%.
Market participants will be closely following the financial results of Adma Biologics in its upcoming release.
For the full year, the Zacks Consensus Estimates are projecting earnings of $0.96 per share and revenue of $639.74 million, which would represent changes of +60% and +25.4%, respectively, from the prior year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Adma Biologics. These revisions help to show the ever-changing nature of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 12.35% higher. Adma Biologics is currently a Zacks Rank #1 (Strong Buy).
Investors should also note Adma Biologics's current valuation metrics, including its Forward P/E ratio of 16.41. For comparison, its industry has an average Forward P/E of 18.67, which means Adma Biologics is trading at a discount to the group.
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 86, positioning it in the top 36% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.